Sold as Fibricor. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Fenofibric Acid (sold as Fibricor), first approved Aug 14, 2009, with 0 new uses approved and 0 published complete response letters.
| Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined DyslipidemiaDyslipidemia, Atherosclerosis · Seoul National University Bundang Hospital | Phase 4 | Recruiting | May 9, 2022 |
| Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsMedulloblastoma Recurrent, Ependymoma Recurrent · Medical University of Vienna | Phase 2 | Recruiting | May 19, 2011 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
